The Metabolic Wave Just Changed Molecules

Metabolic-drug trials in my archive went from 172 in 2023 to 653 in 2025 — nearly 4× in two years. The volume isn’t the signal. The signal is that the molecules driving the next leg aren’t the two everyone already owns.

Semaglutide and tirzepatide — Ozempic, Wegovy, Mounjaro, Zepbound — did roughly $49 billion in sales in 2025 and are among the most-watched assets in any market (Novo Nordisk Annual Report; Lilly via BioPharma Dive). That’s the first act, and at the headline level it is fully priced. What I watch is the layer underneath the revenue — the trials and the research — because it moves first. This quarter it started pointing somewhere specific.

In my archive the metabolic-therapies cluster carries 1,023 cross-source signals. Split by pipeline layer, it is not a marketing wave dressed up as science — it is an evidence engine: 501 registered clinical trials and 495 research papers, with market and press chatter a rounding error against them.

Figure 1 — Where the 1,023 metabolic signals sit

Figure 1: The 1,023-signal metabolic cluster by pipeline layer — 501 registered trials, 495 research papers, everything else a rounding error. A real evidence engine, not a marketing wave. Source: Sovenyr signal graph.

One honest caveat up front: this is my collection, not a census. The layer counts reflect what my sources index and what I cluster under this theme. The shape — trials and research carrying almost everything — is the reliable signal, not the exact integers.

The trials engine is the tell

Marketing can inflate a mention count. It cannot register a clinical trial — that takes a protocol, a sponsor, sites, and patients. So the trial curve is the honest one, and it is bent sharply upward: metabolic-drug trial registrations in my archive climbed from 172 in 2023 to 255 in 2024 to 653 in 2025 — a 2.6× single-year jump, with the inflection squarely in 2024.

Figure 2 — Metabolic-drug clinical trials registered per year

Figure 2: Metabolic-drug clinical-trial registrations in the Sovenyr archive: 172 (2023) → 255 (2024) → 653 (2025), inflection in 2024. 2026 year-to-date. Registrations require patients and protocols — the honest curve. Source: ClinicalTrials.gov via Sovenyr.

That is committed capital and enrolled patients, not sentiment. When the trial layer bends like this, the clinical and commercial consequences run for years, because each trial is a separate readout, a separate label, a separate market.

The second act, by molecule

Here is the cut that stopped me. The incumbents — semaglutide and tirzepatide — plateau at roughly 500 mentions a quarter in my feed; they own the conversation and are not going anywhere. But the next-wave molecules behind them went from a handful of mentions a quarter through 2024 to 19 in 2025-Q4 and 34 in 2026-Q1. A quiet line is starting to bend.

Figure 3 — Next-wave molecule momentum, by quarter

Figure 3: Next-wave molecule mentions per quarter (retatrutide + orforglipron + CagriSema + survodutide) rose 5 → 34 from 2024-Q1 to 2026-Q1 while incumbents plateaued near 500/qtr. 2026-Q2 partial. Source: Sovenyr signal graph.

Four names carry that curve, and each crossed a decisive line in 2025–2026:

• **Oral orforglipron** (Eli Lilly) — the first oral small-molecule GLP-1 through Phase 3; Lilly triggered global obesity submissions at the end of 2025 (Eli Lilly investor).
• **Retatrutide (Lilly’s triple GIP/GLP-1/glucagon agonist) — up to −28.3% mean weight loss** in pivotal Phase 3 TRIUMPH-1 (Eli Lilly / AJMC, May 2026), pushing toward what used to require surgery.
• **CagriSema (Novo) — 22.7% in REDEFINE 1, filed with the FDA in December 2025 (NEJM / HCPLive). [Survodutide](https://pubmed.ncbi.nlm.nih.gov/41855048/)** (Boehringer/Zealand) — positive Phase 3.

Figure 4 — The next wave, by signal volume (trailing 24 months)

Figure 4: Trailing-24-month mentions of the four next-wave molecules in the Sovenyr archive. Small absolute counts — but two are oral and two are triple/dual-agonists, the two axes that break the class open. Source: Sovenyr signal graph.

Notice what the four have in common. Two are oral — and the FDA has already approved an oral semaglutide pill for weight loss, launching January 2026 (Novo / PRNewswire). Two are triple- or dual-agonists reaching efficacy the first generation couldn’t. That is a change in form, not just another dose: one axis reprices access (no needle, no cold chain), the other reprices the efficacy ceiling.

It is also leaking past the label

The same platform pressure shows up in the research mix. Of metabolic-drug papers in my archive over the last year, only about 56% are still about obesity or diabetes — the approved indications. The rest have fanned out: 376 cardio-renal, 166 liver/MASLD, 139 neuro/cognition, 72 oncology, plus muscle-preservation and sleep apnea. GLP-1 signaling is being pulled as a lever on whole-body metabolism, and that fan-out is a second, slower engine underneath the molecule story.

Two normal explanations and one harder one

Normal explanation one: the incumbents keep it. Weight ~30%. Semaglutide and tirzepatide have brand, outcomes data, and manufacturing scale; the next wave stays a footnote. The counter is that the successors are not me-toos — oral and triple-agonist are different products, and each already cleared Phase 3.

Normal explanation two: it’s a hype-research cycle cooling. Weight ~25%. Obesity coverage is saturated and mentions revert. But trial registrations don’t revert on sentiment, and the trial curve is still climbing.

The harder read — and mine: the class is rotating, not peaking. Weight ~45%. The move from injectable dual-agonists to oral pills and triple-agonists expands the addressable population and the efficacy ceiling at the same time, and the pipeline layer is pricing that a year or more before it shows up in anyone’s revenue line.

What I am specifically not claiming

I’m not claiming the next-wave molecules are winners — most spillover and successor programs fail in trials; that’s how drug development works, and Phase 3 success is not a label. I’m not claiming mention counts measure efficacy — they measure attention. And I’m not making a stock call: these are among the most-watched equities on earth and the headline edge is long gone. The under-priced part, if any, is second-order — oral-manufacturing capacity, muscle-preservation, MASLD diagnostics — and that’s a research thread, not a recommendation.

What to watch

• Orforglipron’s FDA decision in 2026 — the first oral GLP-1 approval resets the access economics of the whole class.
• Oral semaglutide uptake after the January 2026 launch — does no-needle widen the market or just cannibalize injections?
• Retatrutide’s label and CagriSema’s FDA decision — if ~23–28% weight loss ships, the efficacy bar for everyone resets.
• My next-wave mention run-rate — if it holds above ~30/quarter and climbs, the second act is structural; if it reverts toward single digits, 2026-Q1 was a spike.

Reproducibility note

Signal figures are from the Sovenyr archive, queried July 2026, and are collection counts, not a census. The 1,023-signal cluster (501 trials / 495 papers), the 2016–2026 trial-registration series (172→255→653), the by-quarter next-wave momentum (semaglutide+tirzepatide vs retatrutide/orforglipron/CagriSema/survodutide, title match), the trailing-24-month molecule counts, and the 365-day indication spread are all reproducible by keyword against CROSSREF, PubMed, ClinicalTrials.gov and our market feeds. External figures verified against 2+ independent references: 2025 sales (Novo AR; Lilly/BioPharma Dive); orforglipron Phase 3 + filing (Eli Lilly investor); oral semaglutide approval (Novo/PRNewswire); retatrutide −28.3% (Eli Lilly/AJMC); CagriSema 22.7% + Dec-2025 filing (NEJM/HCPLive). The interpretive claim — that the class is rotating form rather than peaking — is mine.

Counts are computed from public research, trial and market metadata for 2016 through July 2026. Reading judgments (“second act”, “rotation”, “platform”) are flagged as such. — Andrii

Originally published at https://sovenyr.substack.com.